Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0245 Transporter Info | ||||
| Gene Name | SLC28A2 | ||||
| Protein Name | Concentrative nucleoside transporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs1060896 | ||||
| Site of GPD | chr15:45262069 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>A | ||||
| Minor Allele Frequency | A=0.3131/1568 (Global) | ||||
| Genotype AA | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Gemcitabine | Drug Info | Pancreatic Neoplasm | Irrelevant to the increased drug response in patients (compare with genotypes AC + CC) | [ 1] | |
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Gemcitabine | Drug Info | Non-Small-Cell Lung Carcinoma | Correlated with the decreased drug response in patients (compare with genotypes AA + AC); Correlated with the decreased hematologic toxicity risk in patients (compare with genotypes AA + AC) | [ 2] | |
| Genetic Polymorphism | rs11854484 | ||||
| Site of GPD | chr15:45253280 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | T=0.3029/1517 (Global) | ||||
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Gemcitabine | Drug Info | Non-Small-Cell Lung Carcinoma | Correlated with the decreased drug response in patients (compare with Genotypes CT + TT); Correlated with the decreased hematologic toxicity risk in patients (compare with Genotypes CT + TT) | [ 2] | |
| Genotype TT | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| Ribavirin | Drug Info | Hepatitis C | Correlated with the increased anemia risk in patients (compare with genotypes CC + CT) | [ 3] | |
| Peginterferon alfa-2B | Drug Info | Hepatitis C | Correlated with the increased anemia risk in patients (compare with genotypes CC + CT) | [ 3] | |
| Protease Inhibitors | N.A. | Hepatitis C | Correlated with the increased anemia risk in patients (compare with genotypes CC + CT) | [ 3] | |
| References | |||||
| 1 | Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15;116(22):5325-35. | ||||
| 2 | Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer. 2009 Jan;63(1):121-7. | ||||
| 3 | Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. J Clin Virol. 2015 Jul;68:56-60. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.